NCT05864365View on ClinicalTrials.gov

A Biomarker Study of ATH434 in Participants With MSA

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

February 26, 2025

Study Completion Date

February 26, 2025

Conditions
Multiple System Atrophy
Interventions
DRUG

ATH434

ATH434 taken by mouth two times per day

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

Sponsors
All Listed Sponsors
lead

Alterity Therapeutics

INDUSTRY

NCT05864365 - A Biomarker Study of ATH434 in Participants With MSA | Biotech Hunter | Biotech Hunter